
open access
메뉴
E-ISSN : 2671-6771
This review chronicles the pivotal "firsts" in gene therapy, from early successes like the 1990 ex vivo trial for adenosine deaminase-deficient severe combined immunodeficiency (ADA-SCID) to the profound setbacks that shaped its trajectory. Tragic events, including leukemia from insertional mutagenesis in SCID-X1 trials and the death of Jesse Gelsinger from a catastrophic immune response, forced a critical re-evaluation of vector safety and regulatory oversight. This introspection led to the development of safer adeno-associated virus (AAV) vectors and the landmark success of in vivo therapy with Luxturna for Leber's congenital amaurosis. The path to commercial viability saw the failure of Glybera contrasted with the blockbuster success of Zolgensma for spinal muscular atrophy, paving the way for the current era of CRISPR-based gene editing with the approval of Casgevy. This history reveals a field matured through adversity, now delivering transformative therapies while still facing critical challenges in cost, immunogenicity, and long-term durability.